The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study to evaluate safety, tolerability, pharmacokinetics, and efficacy of SER-155 in adults undergoing hematopoietic stem cell transplantation to reduce the risk of infection and graft versus host disease (NCT04995653).
 
Doris M. Ponce
Consulting or Advisory Role - ceramedix; Generon; Kadmon
Research Funding - Incyte; Takeda (Inst)
 
Mary-Jane Lombardo
Employment - Prolacta Bioscience (I); Seres Therapeutics
Stock and Other Ownership Interests - Seres Therapeutics
 
Christopher B. Ford
Employment - Seres Therapeutics
Stock and Other Ownership Interests - Seres Therapeutics
 
Jonathan U. Peled
Stock and Other Ownership Interests - Postbiotics Inc.; Seres Therapeutics (Inst)
Consulting or Advisory Role - CSL Behring; Da Volterra; MaaT Pharma
Research Funding - Seres Therapeutics
Patents, Royalties, Other Intellectual Property - filed intellectual property applications related to the microbiome; IP licensing fees, Seres Therapeutics
Travel, Accommodations, Expenses - Seres Therapeutics
 
Marcel R. M. Van Den Brink
Honoraria - BeiGene (I); Ceramedix; Da Volterra; Forty Seven; Frazier Healthcare Partners; GlaxoSmithKline; Lygenesis; Magenta Therapeutics; Merck; Nektar; Notch Therapeutics; Novartis (I); Pluto Immunotherapeutics; Priothera; Rheos Medicines; Seres Therapeutics; Synthekine (I); WindMIL; WindMIL
Consulting or Advisory Role - Seres Therapeutics
Research Funding - Seres Therapeutics
Patents, Royalties, Other Intellectual Property - Dr. van den Brink receives royalties from Wolters Kluwer, and he has intellectual property Licensing with Seres Therapeutics and Juno Therapeutics
Travel, Accommodations, Expenses - Rheos Medicines
Other Relationship - DKMS
(OPTIONAL) Uncompensated Relationships - Notch Therapeutics; Pluto Immunotherapeutics; Seres therapeutics
 
Bindu Tejura
Employment - Seres Therapeutics
Stock and Other Ownership Interests - Cyclerion; Finch Therapeutics; Ironwood Pharmaceuticals; Seres Therapeutics; Summit Therapeutics